Abstract 546P
Background
More than 70% of patients with T1 colorectal cancer (CRC) undergo a radical surgery involving lymph node dissection, despite the presence of lymph node metastasis (LNM) being observed in only ∼10% of cases. To reduce unnecessary radical surgery, we developed a multimodal artificial intelligence (AI) system to identify T1 CRC at risk for LNM.
Methods
We analyzed 402 CRC patients from two independent multicenter cohorts, including a training (n = 219) and a validation cohort (n = 183). Proteomics dataset from tumor tissue were identified and quantified using LC-MS/MS analysis. Multiple pathomics features were extracted from whole H&E slides with patch-level convolutional neural network training in weakly supervised manner. Clinicopathological characteristics included age, tumor size, location, lymphatic and vascular invasion, perineural invasion, histologic grade, and CEA. A machine-learning artificial neural network using proteomics, pathomics and clinicopathological features was developed.
Results
LNM were detected in 78 out of 219 patients (35.6%) within the training cohort and in 29 out of 183 patients (15.8%) within the validation cohort. A panel of six protein biomarkers (OSBPL5, ATAD2, BAIAP2, MANBA, ITPR2, ARHGAP5) screened by proteomics was quantified by immunohistochemistry and subsequently integrated into the AI system. In the validation cohort, the multimodal AI system achieved robust classification of LNM status, yielding an AUC of 0.978. In comparison, the guideline-based model exhibited an AUC of 0.717 for identifying LNM (P < 0.001).
Conclusions
The AI system integrating deep learning-proteomics, pathomics and clinicopathological features robustly identifies T1 CRC patients at risk of LNM in a preoperative setting. The multimodal AI system would improve clinical practice by alleviating the burden of unnecessary overtreatment for T1 CRC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Jianmin Xu.
Funding
The National Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
423P - Marginalization and factors associated with early mortality among patients diagnosed with de novo metastatic breast cancer in Ontario, Canada
Presenter: Priya Thomas
Session: Poster session 15
425P - The humanitarian PACT for advanced breast cancer: A multi-stakeholder collaboration to improve access to treatment in low- and middle-income countries
Presenter: Alicia Annamalay
Session: Poster session 15
426P - Impact of statin therapy on mortality and recurrence in female breast cancer: A meta-analysis
Presenter: Maria Eduarda Souza
Session: Poster session 15
427P - The role of patient navigation (PN) in delivering goal-concordant care to advanced breast cancer (ABC) patients
Presenter: Akshara Singareeka Raghavendra
Session: Poster session 15
428P - Key landmarks of male advanced breast cancer: Results of the GEICAM/2016-04 study
Presenter: Noelia Martinez
Session: Poster session 15
429P - Brain imaging screening (BIS) in metastatic breast cancer (MBC): Patients’ and physicians’ perspectives
Presenter: Ana Leonor Matos
Session: Poster session 15
430P - A novel survival predicting model for breast cancer brain metastasis based on multimodal data
Presenter: Zisheng Wu
Session: Poster session 15
431P - Exposure-adjusted incidence rates (EAIRs) of adverse events (AEs) from the TROPION-Breast01 study of datopotamab deruxtecan (Dato-DXd) vs investigator’s choice of chemotherapy (ICC) in patients (pts) with pretreated, inoperable/metastatic HR+/HER2– breast cancer (BC)
Presenter: Hope Rugo
Session: Poster session 15
432P - Exploratory biomarker analysis of trastuzumab deruxtecan versus treatment of physician’s choice in HER2-low, hormone receptor–positive metastatic breast cancer in DESTINY-Breast04
Presenter: Naoto Ueno
Session: Poster session 15
433TiP - Phase III, randomized, open-label TroFuse-010 Study of sacituzumab tirumotecan (sac-TMT) alone and with pembrolizumab vs treatment of physician’s choice chemotherapy (TPC) in patients with HR+/HER2- unresectable locally advanced or metastatic breast cancer (mBC)
Presenter: Sara Tolaney
Session: Poster session 15